HTA
CRL icon

Haber Trilix Advisors’s Charles River Laboratories CRL Stock Holding History

Haber Trilix Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$189K Buy
+4,600
New +$197K 0.02% 119

Other funds holding CRL

PIM
Perkins Investment Management Chicago, Illinois $8.09B AUM 25.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
FC
Fairpointe Capital Chicago, Illinois $66.3M AUM 101.32% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Haber Trilix Advisors's CRL Position: Q2 2013 in Review

Haber Trilix Advisors opened a new position in Charles River Laboratories (CRL) in Q2 2013: 4,600 shares worth $189K. The stake represents 0.02% of the portfolio and ranks #119 among its holdings.

225 funds tracked by Wall St. Rank hold CRL as of Q2 2013.

  • Haber Trilix Advisors held 4,600 shares of Charles River Laboratories worth $189K as of Q2 2013.
  • Charles River Laboratories was a new Haber Trilix Advisors position in Q2 2013.
  • Charles River Laboratories made up 0.02% of Haber Trilix Advisors's portfolio in Q2 2013, its #119 holding.
  • 225 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2013.

Based on Haber Trilix Advisors's 13F filing for Q2 2013, filed 14 Aug 2013.